1-20 of 8348
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Images
OS and PFS in transplant-eligible patients.  (A) OS Kaplan-Meier stratified...
Published: 2020
Figure 1. OS and PFS in transplant-eligible patients. (A) OS Kaplan-Meier stratified by time period. (B) Three-year OS landmark Kaplan-Meier stratified by time period. (C) PFS Kaplan-Meier stratified by time period, restricted to patients on a TT protocol. (D) Three-year PFS landmark Kaplan-Meie... More
Images
Cumulative relative survival.  (A) Cumulative relative survival restricted ...
Published: 2020
Figure 2. Cumulative relative survival. (A) Cumulative relative survival restricted to patients younger than 65 years of age (n = 3123). (B) Cumulative relative survival restricted to patients 65 or older (n = 1206). Cumulative relative survival shows the ratio of the observed survival in the UA... More
Images
Images
Images
Images
Comparison of hemostatic markers among groups at presentation demonstrated ...
Published: 2020
Figure 1. Comparison of hemostatic markers among groups at presentation demonstrated significant differences between groups. (A) VWF:Ag. (B) VWF:Ac. (C) FVIII. (D) ADAMTS13Ac. IS demonstrates the highest median VWF:Ag (196.9IU/dl), VWF:Ac (188.8IU/dL) and FVIII (178.6IU/dL), followed by TIA (VWF... More
Images
Longitudinal patterns in ischemic stroke.  Longitudinal changes in all haem...
Published: 2020
Figure 2. Longitudinal patterns in ischemic stroke. Longitudinal changes in all haemostatic markers were measured at presentation (t0), 24 hours later (t1), 48 hours post presentation (t2), 5-7 days post presentation (t3) and final follow up from 6 weeks post presentation (t4). Median follow up ... More
Images
Mortality outcome: difference in baseline hemostatic markers in IS and TIA ...
Published: 2020
Figure 3. Mortality outcome: difference in baseline hemostatic markers in IS and TIA groups combined. Significant differences were seen in all haemostatic markers at baseline between those patients whom had subsequently died at final follow up (n =2 4) vs those whom survived (n = 156) at a media... More
Images
Visual overview of posttransplant IR in terms of time and graft source.  Co...
Published: 2020
Figure 1. Visual overview of posttransplant IR in terms of time and graft source. Comprehensive IR data are summarized in supplemental Table 2. (A-B) ALC and CD20 + B- cell, CD4 + CD45RA + T-cell, and NK-cell counts (expressed as CD3 − CD56 + and CD16 + CD57 − ) were significantly higher duri... More
Images
Contribution of immune cell subsets to posttransplant outcomes.  (A) Forest...
Published: 2020
Figure 2. Contribution of immune cell subsets to posttransplant outcomes. (A) Forest plot of multivariate analysis results for posttransplant outcomes. (B) Heat map showing similarity in immune cells confirmed after posttransplant events (sorted hierarchically by HR). These results revealed that... More
Images
Expansion of key cell subsets; namely, CD20   +   B cells, CD8   +   CD11b ...
Published: 2020
Figure 3. Expansion of key cell subsets; namely, CD20 + B cells, CD8 + CD11b − T cells, and CD16 + CD57 − NK cells, significantly positively affected 2-year OS. There were no significant differences in CIR or proportions of high vs low cell counts for CD20 + B cell and CD8 + CD1... More
Images
Survival curves after allogeneic HSCT.  (A) OS and DFS were significantly b...
Published: 2020
Figure 4. Survival curves after allogeneic HSCT. (A) OS and DFS were significantly better with rapid NK cell recovery. (B) Early IR of CD20 + B cells yielded longer OS and NRM even in patients with higher HCT-CI (≥3). More
Images
Effect of graft source on the following outcomes after allogeneic HSCT.  OS...
Published: 2020
Figure 5. Effect of graft source on the following outcomes after allogeneic HSCT. OS (A), CI-NRM (B), CI-relapse (C), acute grade 2 to 4 GVHD (D) and grade 3 to 4 GVHD (E), and chronic GVHD (F). Graft source–related outcomes were confirmed for OS, cumulative incidence of acute GVHD (≥grade 3), a... More
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Images
Images
RCTs on ruxolitinib (Rux).  Annual incidence of thrombosis per study per ar...
Published: 2020
Figure 2. RCTs on ruxolitinib (Rux). Annual incidence of thrombosis per study per arm with binomial CIs and corresponding calculated RRs. More